Post complete response letter issued by the USFDA to NOVOB for Tresiba and Ryzodeg, we reduce our PT for NOVOB from DKK 1000 to DKK 950. Considering the US constitutes the biggest long acting insulin market (Lantus-US sales: $4b; Western EU: $1.0b; RoW: $400m; Emerg mkt: $1.0b), the CRL has clouded the optimism over revenue potential of this important pipeline asset. We had forecasted a slow ramp up and peak sales of $1.5b (incremental sales for Tresiba / Ryzodeg excluding cannibalization of Levemir), which we now reduce to $500million. Although the delay does not have any impact on near term earnings, but has long term implications for market share in a competitive next generation insulin market. We expect a 3-4 years delay would put NOVOB behind SAN and LLY in the launch of next generation insulin.
NOVO NORDISK , SANOFI – Tresiba and Ryzodeg delayed in the US: Lantus protected – Reduce PT to DKK 950
Date:
2015-07
MORE PUBLICATIONS
Categories
- Automotive
- Bearings
- Business Services
- Chemicals and Materials
- Coatings
- Company Profiles
- Consumer Goods
- Defense
- Electronics
- Energy
- Financial Services
- Food & Beverages
- Manufacturing & Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Public Sector
- Resins
- Technology
- Telecommunications and Wireless
- Vacuum Products
Popular Articles
- Mayo Clinic – Strategic SWOT Analysis Review
- AMC Entertainment, Inc. – Strategic SWOT Analysis Review
- Global Energy Drink Market Will Grow At A CAGR Of Approximately 8.6%
- Global Disposable Diapers Market Analysis
- NVIDIA Corporation (NVDA) – Financial and Strategic SWOT Analysis Review
- Sprint Corporation (S) – Financial and Strategic SWOT Analysis Review
- 2017年全球智能温室系统(Smart Greenhouse System)市场及投资分析报告(优惠版)
- Global Blockchain Technology Market Worth $ 5.6 Billion by 2022
- Global Hematology Market Analysis by Technology
- Global In Vitro Diagnostics (IVD) Market Analysis By Technology